Literature DB >> 11553525

Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder.

O A De León1.   

Abstract

Both traditional and newer antiepileptic drugs have been considered for the acute and maintenance treatment of bipolar disorder. Although the psychotropic actions of these compounds have long been recognized, their specific mood-stabilizing properties have become evident only relatively recently. Carbamazepine and valproate are the antiepileptics most thoroughly studied for the treatment of bipolar disorder, but trials of the newer compounds such as lamotrigine, gabapentin, topiramate, and tiagabine have also begun to emerge. This article reviews the published research (including controlled trials, outcome reports, case series, and anecdotal observations) relevant to the efficacy of these agents in the acute and maintenance treatment of bipolar disorder. It also reviews the available information regarding clinical predictors of response. Despite considerable interest in these drugs, data are still limited. Comparison of clinical responses to the various mood stabilizers and determination of their mechanisms of action could help to improve treatment for bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553525     DOI: 10.1093/hrp/9.5.209

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  9 in total

1.  Psychotropic effects of antiepileptic drugs.

Authors:  Siddhartha Nadkarni; Orrin Devinsky
Journal:  Epilepsy Curr       Date:  2005 Sep-Oct       Impact factor: 7.500

2.  Managing bipolar depression.

Authors:  Raymond Pary; Paul R Matuschka; Susan Lewis; Steven Lippmann
Journal:  Psychiatry (Edgmont)       Date:  2006-02

3.  Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder.

Authors:  Norio Yasui-Furukori; Naoto Adachi; Yukihisa Kubota; Takaharu Azekawa; Eiichiro Goto; Koji Edagawa; Eiichi Katsumoto; Seiji Hongo; Hitoshi Ueda; Kazuhira Miki; Masaki Kato; Reiji Yoshimura; Atsuo Nakagawa; Toshiaki Kikuchi; Takashi Tsuboi; Koichiro Watanabe; Kazutaka Shimoda
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-11-30       Impact factor: 2.582

4.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 5.  Treating bipolar disorder. Evidence-based guidelines for family medicine.

Authors:  Roger S McIntyre; Deborah A Mancini; Peter Lin; John Jordan
Journal:  Can Fam Physician       Date:  2004-03       Impact factor: 3.275

Review 6.  Bipolar disorder.

Authors:  John R Geddes; David Briess
Journal:  BMJ Clin Evid       Date:  2007-08-01

7.  Mood Disorders in Family Practice: Beyond Unipolarity to Bipolarity.

Authors:  J Sloan Manning; Saeeduddin Ahmed; Hillary C. McGuire; Donald P. Hay
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-08

8.  Regulation of alternative splicing in obesity-induced hypertension.

Authors:  Zodwa Dlamini; Rodney Hull; Tshepiso J Makhafola; Mzwandile Mbele
Journal:  Diabetes Metab Syndr Obes       Date:  2019-08-28       Impact factor: 3.168

9.  The influence of continuous prenatal exposure to valproic acid on physical, nociceptive, emotional and psychomotor responses during adolescence in mice: Dose-related effects within sexes.

Authors:  Jelena Podgorac; Slobodan Sekulić; Branka Petković; Gordana Stojadinović; Ljiljana Martać; Vesna Pešić
Journal:  Front Behav Neurosci       Date:  2022-09-29       Impact factor: 3.617

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.